Literature DB >> 2685273

Gastroduodenal ulceration in dogs. Retrospective study of 43 cases and literature review.

M E Stanton1, R M Bright.   

Abstract

Forty three dogs with non-neoplastic canine gastric and/or duodenal ulcers were diagnosed at the University of Tennessee Veterinary Teaching Hospital (UTVTH) and reviewed in conjunction with dogs reported in the literature. No age, sex, or breed predilection was found. Most of the 43 UTVTH dogs presented with clinical signs referable to gastrointestinal disease, but evidence of hemorrhage was not always present. Nonregenerative anemia was a common (33/43 dogs) finding. Diagnosis of ulcer disease was made by contrast radiography, with clinical evidence of gastrointestinal hemorrhage, or surgery, endoscopy, or necropsy. Treatment with nonsteroidal, anti-inflammatory drugs (NSAIDs) and hepatic disease were the two most common predisposing factors for ulcer disease. Dogs with liver disease tended to have duodenal ulcers, dogs receiving NSAID treatment tended to have pyloroantral ulcers, and dogs with mastocytosis had ulcers in multiple locations. Three dogs with duodenal ulcers receiving NSAID treatment had an additional predisposing factor. Surgical treatment (with or without medical treatment) had a good outcome when the predisposing factors could be controlled or eliminated. Only 3 of 27 dogs in both the surgical and medically treated groups died from ulcer disease, whereas 6 of 16 dogs in the untreated group died from ulcer disease.

Entities:  

Mesh:

Year:  1989        PMID: 2685273     DOI: 10.1111/j.1939-1676.1989.tb00863.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  13 in total

1.  Challenging diagnosis--icterus associated with a single perforating duodenal ulcer after long-term nonsteroidal antiinflammatory drug administration in a dog.

Authors:  Felix M Duerr; Anthony P Carr; Trevor N Bebchuk; Neil C Pople
Journal:  Can Vet J       Date:  2004-06       Impact factor: 1.008

2.  Effect of sucralfate on gastric permeability in an ex vivo model of stress-related mucosal disease in dogs.

Authors:  Tracy L Hill; B Duncan X Lascelles; Anthony T Blikslager
Journal:  J Vet Intern Med       Date:  2018-02-20       Impact factor: 3.333

3.  Pharmacokinetics of esomeprazole following intravenous and oral administration in healthy dogs.

Authors:  Emily K Cook; Nana Satake; Ben W Sykes; Emma L Bennett; Paul C Mills
Journal:  Vet Med (Auckl)       Date:  2016-08-31

4.  Prevalence of gastrointestinal lesions in dogs chronically treated with nonsteroidal anti-inflammatory drugs.

Authors:  Kasey Mabry; Tracy Hill; Mary Katherine Tolbert
Journal:  J Vet Intern Med       Date:  2021-02-03       Impact factor: 3.333

5.  Serum concentrations of gastrin after famotidine and omeprazole administration to dogs.

Authors:  N L Parente; N Bari Olivier; K R Refsal; C A Johnson
Journal:  J Vet Intern Med       Date:  2014-07-23       Impact factor: 3.333

Review 6.  Hepatic Fibrosis in Dogs.

Authors:  V M Eulenberg; J A Lidbury
Journal:  J Vet Intern Med       Date:  2017-11-30       Impact factor: 3.333

7.  ACVIM consensus statement: Support for rational administration of gastrointestinal protectants to dogs and cats.

Authors:  Stanley L Marks; Peter H Kook; Mark G Papich; M K Tolbert; Michael D Willard
Journal:  J Vet Intern Med       Date:  2018-10-31       Impact factor: 3.333

8.  Gastrojejunostomy without partial gastrectomy to manage duodenal stenosis in a dog.

Authors:  Johannes J Nel; Cornelius J du Plessis; Gert L Coetzee
Journal:  J S Afr Vet Assoc       Date:  2015-12-09       Impact factor: 1.474

9.  Evaluation of the adverse effects of oral firocoxib in healthy dogs.

Authors:  P V M Steagall; F B Mantovani; T H Ferreira; E S Salcedo; F Q Moutinho; S P L Luna
Journal:  J Vet Pharmacol Ther       Date:  2007-06       Impact factor: 1.786

10.  Prospective observational study of the use of omeprazole and maropitant citrate in veterinary specialist care.

Authors:  Rachel McCormack; Louise Olley; Barbara Glanemann; James W Swann
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.